DZ2376A1
(fr)
*
|
1996-12-19 |
2002-12-28 |
Smithkline Beecham Plc |
Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
|
JP2002511097A
(ja)
*
|
1997-07-11 |
2002-04-09 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
5−ht▲下6▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法
|
JP4253126B2
(ja)
|
1998-01-29 |
2009-04-08 |
アムジェン インコーポレイテッド |
Ppar−ガンマ調節剤
|
GB9803411D0
(en)
*
|
1998-02-18 |
1998-04-15 |
Smithkline Beecham Plc |
Novel compounds
|
US6194410B1
(en)
|
1998-03-11 |
2001-02-27 |
Hoffman-La Roche Inc. |
Pyrazolopyrimidine and pyrazolines and process for preparation thereof
|
GB9810671D0
(en)
*
|
1998-05-18 |
1998-07-15 |
Pfizer Ltd |
Anti-pruritic agents
|
GB9818914D0
(en)
*
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
GB9818916D0
(en)
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
GB9820113D0
(en)
|
1998-09-15 |
1998-11-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
US7041691B1
(en)
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
GB9926302D0
(en)
*
|
1999-11-05 |
2000-01-12 |
Smithkline Beecham Plc |
Novel compounds
|
WO2001045694A1
(fr)
*
|
1999-12-21 |
2001-06-28 |
Smithkline Beecham Corporation |
Antagonistes des recepteurs de l'urotensine ii
|
SE9904723D0
(sv)
*
|
1999-12-22 |
1999-12-22 |
Carlsson A Research Ab |
New modulators of dopamine neurotransmission II
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
SE0002739D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New use
|
US6818639B2
(en)
|
2000-07-21 |
2004-11-16 |
Biovitrum Ab |
Pharmaceutical combination formulation and method of treatment with the combination
|
SE0002754D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New pharmaceutical combination formulation and method of treatment with the combination
|
US6399617B1
(en)
|
2000-07-21 |
2002-06-04 |
Biovitrum Ab |
Use
|
DE60142914D1
(de)
*
|
2000-09-18 |
2010-10-07 |
Toa Eiyo Ltd |
N-substituierte benzothiophensulfonamid-derivate
|
US7071220B2
(en)
|
2000-09-18 |
2006-07-04 |
Toa Eiyo Ltd. |
N-substituted benzothiophenesulfonamide derivatives
|
US7034029B2
(en)
|
2000-11-02 |
2006-04-25 |
Wyeth |
1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
|
EP1341783A1
(fr)
|
2000-11-21 |
2003-09-10 |
Smithkline Beecham Plc |
Derives d'isoquinoleine utiles pour le traitement de troubles du systeme nerveux central
|
CN1289072C
(zh)
|
2000-12-22 |
2006-12-13 |
石原产业株式会社 |
苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
|
AU2002256418A1
(en)
*
|
2001-04-27 |
2002-11-11 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of bace
|
JP2004529164A
(ja)
*
|
2001-05-07 |
2004-09-24 |
スミスクライン・ビーチャム・コーポレイション |
スルホンアミド
|
WO2002089785A1
(fr)
*
|
2001-05-07 |
2002-11-14 |
Smithkline Beecham Corporation |
Sulfonamides
|
AR033879A1
(es)
|
2001-05-07 |
2004-01-07 |
Smithkline Beecham Corp |
Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
|
EP1385830A4
(fr)
*
|
2001-05-07 |
2005-08-17 |
Smithkline Beecham Corp |
Sulfonamides
|
US6743796B2
(en)
*
|
2001-05-07 |
2004-06-01 |
Wyeth |
Piperazinyl-isatins
|
EP1385495A4
(fr)
*
|
2001-05-07 |
2005-12-21 |
Smithkline Beecham Corp |
Sulfonamides
|
GB0111186D0
(en)
*
|
2001-05-08 |
2001-06-27 |
Smithkline Beecham Plc |
Novel compounds
|
US7718650B2
(en)
|
2001-05-11 |
2010-05-18 |
Biovitrum Ab |
Aryl sulfonamide compounds for treating obesity
|
RS88803A
(en)
*
|
2001-05-11 |
2007-02-05 |
Biovitrum Ab., |
Novel-arylsulfonamide compounds for the treatment of obesity type ii diabetes and cns-disorders
|
CA2443724C
(fr)
*
|
2001-05-11 |
2009-11-03 |
Patrizia Caldirola |
Composes arylsulfonamide pour le traitement de l'obesite, de diabetes de type ii et de troubles du systeme nerveux central
|
ES2280546T3
(es)
|
2001-06-07 |
2007-09-16 |
F. Hoffmann-La Roche Ag |
Nuevos derivados de indol con afinidad por el receptor 5-ht6.
|
KR100888906B1
(ko)
|
2001-06-11 |
2009-03-16 |
바이오비트럼 에이비(피유비엘) |
치환 술폰아미드 화합물, cns 장애, 비만 및 ⅱ 형당뇨병 치료용 약제로서의 이들의 사용 방법
|
DE60212841T2
(de)
|
2001-06-15 |
2007-06-21 |
F. Hoffmann-La Roche Ag |
4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
|
US6727264B1
(en)
|
2001-07-05 |
2004-04-27 |
Synaptic Pharmaceutical Corporation |
Substituted anilinic piperidines as MCH selective antagonists
|
US20040242589A1
(en)
*
|
2001-08-07 |
2004-12-02 |
Bromidge Steven Mark |
3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
|
AU2002340804B2
(en)
|
2001-08-10 |
2008-04-03 |
F. Hoffmann-La Roche Ag |
Arylsulfonyl derivatives with 5-HT6 receptor affinity
|
ATE380028T1
(de)
|
2001-09-05 |
2007-12-15 |
Eisai R&D Man Co Ltd |
Mittel zur anregung des appetits und mittel zur behandlung von anorexie
|
SE0103644D0
(sv)
*
|
2001-11-01 |
2001-11-01 |
Astrazeneca Ab |
Therapeutic isoquinoline compounds
|
DE60232173D1
(de)
*
|
2001-11-09 |
2009-06-10 |
Biovitrum Ab Publ |
Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
|
RS44204A
(en)
|
2001-11-22 |
2007-06-04 |
Biovitrum Ab., |
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
|
RS44304A
(en)
|
2001-11-22 |
2007-06-04 |
Biovitrum Ab., |
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
|
CN1321115C
(zh)
*
|
2001-11-30 |
2007-06-13 |
霍夫曼-拉罗奇有限公司 |
作为哮喘治疗中的ccr-3受体拮抗剂的哌嗪衍生物
|
MXPA04007612A
(es)
*
|
2002-02-05 |
2004-11-10 |
Novo Nordisk As |
Aril- y heteroarilpiperazinas novedosas.
|
AU2003244452A1
(en)
*
|
2002-02-05 |
2003-09-02 |
Glaxo Group Limited |
Method of promoting neuronal growth
|
CN1630642A
(zh)
*
|
2002-02-13 |
2005-06-22 |
葛兰素集团有限公司 |
苯磺酰胺衍生物
|
WO2003068751A1
(fr)
*
|
2002-02-13 |
2003-08-21 |
Glaxo Group Limited |
Derives de 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine presentant une affinite pour le recepteur 5-ht6, destines au traitement de troubles du snc
|
AU2003218660A1
(en)
*
|
2002-02-13 |
2003-09-04 |
Glaxo Group Limited |
Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds
|
JP4455064B2
(ja)
|
2002-03-27 |
2010-04-21 |
グラクソ グループ リミテッド |
キノリン誘導体および5−ht6リガンドとしてのその使用
|
US20040142948A1
(en)
*
|
2002-05-07 |
2004-07-22 |
Dashyant Dhanak |
Sulfonamides
|
DE60303376T2
(de)
*
|
2002-05-13 |
2006-11-16 |
F. Hoffmann-La Roche Ag |
Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
|
EP1897881A3
(fr)
|
2002-06-20 |
2009-03-18 |
Biovitrum AB (publ) |
Composés utiles pour le traitement de l'obésité, du diabète de type II et des troubles du système nerveux central
|
WO2004000828A1
(fr)
*
|
2002-06-20 |
2003-12-31 |
Biovitrum Ab |
Composes utiles pour le traitement de l'obesite, du diabete de type ii et des troubles du systeme nerveux central
|
US7943639B2
(en)
*
|
2002-06-20 |
2011-05-17 |
Proximagen Limited |
Compounds
|
KR20050073560A
(ko)
|
2002-10-18 |
2005-07-14 |
에프. 호프만-라 로슈 아게 |
5-ht6 수용체 친화성을 갖는 4-피페라진일 벤젠설폰일인돌
|
AU2003291262A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Smithkline Beecham Corporation |
Sulfonamides
|
AU2003295408A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Smithkline Beecham Corporation |
Sulfonamides
|
GEP20084540B
(en)
|
2003-01-14 |
2008-11-25 |
Arena Pharm Inc |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
US7153858B2
(en)
|
2003-01-31 |
2006-12-26 |
Epix Delaware, Inc. |
Arylpiperazinyl compounds
|
US20060257613A1
(en)
*
|
2003-02-13 |
2006-11-16 |
Horst Berneth |
Metal complexes as light-absorbing compounds in the information layer of optical data carriers
|
JP5008025B2
(ja)
*
|
2003-02-20 |
2012-08-22 |
エンサイシブ・ファーマシューティカルズ・インコーポレイテッド |
フェニレンジアミンウロテンシン−ii受容体拮抗薬およびccr−9拮抗薬
|
TWI289141B
(en)
*
|
2003-03-11 |
2007-11-01 |
Hoffmann La Roche F. Ag. |
Quinolinone derivatives and uses thereof
|
US7262197B2
(en)
*
|
2003-03-31 |
2007-08-28 |
Janssen Pharmaceutica, N.V |
Phospholipase C inhibitors for use in treating inflammatory disorders
|
US6946466B2
(en)
*
|
2003-04-10 |
2005-09-20 |
Schering Ag |
Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
|
US20040204422A1
(en)
*
|
2003-04-14 |
2004-10-14 |
Abbott Gmbh & Co. Kg. |
N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
|
EA009732B1
(ru)
|
2003-07-22 |
2008-02-28 |
Арена Фармасьютикалз, Инк. |
Диарильные и арилгетероарильные производные мочевины в качестве модуляторов 5-ht-рецептора серотонина, пригодные для профилактики и лечения связанных с ним заболеваний
|
GB0320320D0
(en)
*
|
2003-08-29 |
2003-10-01 |
Glaxo Group Ltd |
Novel compounds
|
US7223761B2
(en)
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
SE0303480D0
(sv)
*
|
2003-12-19 |
2003-12-19 |
Biovitrum Ab |
Benzofuranes
|
AU2004299438A1
(en)
*
|
2003-12-19 |
2005-06-30 |
Biovitrum Ab |
Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder
|
US7381728B2
(en)
*
|
2004-07-28 |
2008-06-03 |
Glaxo Group Limited |
Piperazine derivatives useful for the treatment of gastrointestinal disorders
|
EP2301625B1
(fr)
|
2004-09-30 |
2017-07-19 |
F. Hoffmann-La Roche AG |
Compositions et procedes pour le traitement de troubles cognitifs
|
BRPI0515998A
(pt)
|
2004-10-14 |
2008-08-19 |
Abbott Gmbh & Co Kg |
compostos heterocìclicos adequados para tratar desordens que respondem à modulação do receptor d3 de dopamina
|
JP4754570B2
(ja)
|
2004-10-14 |
2011-08-24 |
アボット ゲーエムベーハー ウント カンパニー カーゲー |
ドーパミンd3受容体の調節に応答する障害の治療に好適なアザビシクロヘプチル化合物
|
WO2006062481A1
(fr)
*
|
2004-12-09 |
2006-06-15 |
Biovitrum Ab |
Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central
|
EP1676841A1
(fr)
*
|
2004-12-30 |
2006-07-05 |
Esteve Laboratorios Dr. Esteve S.A. |
Composés substitués type sulphonamide d'indazole ou sulphonamide de 2,3-dihydroindole, leur préparation et leur utilisation comme médicaments
|
KR100931928B1
(ko)
*
|
2005-01-12 |
2009-12-15 |
인제대학교 산학협력단 |
P25/cdk5 저해 화합물을 포함하는 퇴행성 뇌질환의 예방 및치료용 약학 조성물
|
AU2006264966B2
(en)
|
2005-07-04 |
2013-02-21 |
High Point Pharmaceuticals, Llc |
Histamine H3 receptor antagonists
|
EP1919896B1
(fr)
|
2005-08-12 |
2009-12-23 |
Suven Life Sciences Limited |
Dérivés de sulphonamide aminoaryles comme ligands fonctionnels 5-ht6.
|
US7923566B2
(en)
|
2005-08-16 |
2011-04-12 |
Suven Life Sciences Limited |
Alternative process for the preparation of losartan
|
WO2007076875A2
(fr)
*
|
2006-01-06 |
2007-07-12 |
Aarhus Universitet |
Composes agissant sur le transporteur de la serotonine
|
TW200808709A
(en)
|
2006-03-31 |
2008-02-16 |
Glaxo Group Ltd |
Novel compounds
|
AR060526A1
(es)
|
2006-04-19 |
2008-06-25 |
Abbott Gmbh |
Compuestos heterociclicos para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6
|
WO2007118900A1
(fr)
|
2006-04-19 |
2007-10-25 |
Abbott Gmbh & Co. Kg |
Composés hétérocycliques pouvant être utilisés pour traiter des troubles qui répondent à la modulation du récepteur de sérotonine 5ht6
|
US8318927B2
(en)
|
2006-05-23 |
2012-11-27 |
High Point Pharmaceuticals, Llc |
6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament
|
SI2079732T1
(sl)
|
2006-05-29 |
2012-03-30 |
High Point Pharmaceuticals Llc |
benzodioksol il ciklopropilpiperazin il piridazin njegove soli in solvati in njegova uporaba kot antagonist histaminskega receptorja H
|
WO2008052190A2
(fr)
|
2006-10-26 |
2008-05-02 |
Flynn Gary A |
Modulateurs d'aquaporine et procédés pour leur utilisation pour le traitement d'un oedème et d'un déséquilibre de fluides
|
CA2670717C
(fr)
|
2007-01-08 |
2012-01-10 |
Suven Life Sciences Limited |
Composes 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole et leur utilisation en tant que ligands de 5-ht6
|
CA2674644A1
(fr)
*
|
2007-01-10 |
2008-07-17 |
F. Hoffmann-La Roche Ag |
Derives de sulfonamide en tant qu'inhibiteurs de la chymase
|
MX2009010242A
(es)
|
2007-03-23 |
2009-12-14 |
Abbott Gmbh & Co Kg |
Compuestos de azetidina adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
|
DK2155674T3
(da)
|
2007-05-03 |
2011-09-26 |
Suven Life Sciences Ltd |
Aminoalkoxy-aryl-sulfonamidforbindelser og anvendelse heraf som 5-HT6-ligander
|
EP2014656A3
(fr)
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
Nouveaux antagonistes d'hétéocycliques h3
|
DE602007012683D1
(de)
*
|
2007-07-19 |
2011-04-07 |
Esteve Labor Dr |
Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
|
BRPI0816571A2
(pt)
|
2007-10-26 |
2015-12-22 |
Suven Life Sciences Ltd |
"composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6"
|
PA8802201A1
(es)
*
|
2007-11-02 |
2009-06-23 |
Abbott Gmbh & Co Kg |
Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
|
WO2009074607A1
(fr)
|
2007-12-12 |
2009-06-18 |
Glaxo Group Limited |
Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
WO2009123714A2
(fr)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
|
EP2288345B1
(fr)
|
2008-04-18 |
2015-06-10 |
University College Dublin National University Of Ireland, Dublin |
Produits psycho-pharmaceutiques
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
BRPI0915205A2
(pt)
*
|
2008-06-11 |
2017-03-21 |
Dana Farber Cancer Inst Inc |
compostos e composições úteis para o tratamento de malária
|
KR101308819B1
(ko)
*
|
2008-09-17 |
2013-09-13 |
수벤 라이프 사이언시스 리미티드 |
아릴 술폰아미드 아민 화합물 및 5-ht6 리간드로서의 용도
|
US8318725B2
(en)
|
2008-09-17 |
2012-11-27 |
Suven Life Sciences Limited |
Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
UA100192C2
(en)
|
2008-11-11 |
2012-11-26 |
УАЙТ ЭлЭлСи |
1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
|
KR101073703B1
(ko)
|
2009-04-07 |
2011-10-14 |
한국화학연구원 |
피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
|
CA2759491A1
(fr)
*
|
2009-04-30 |
2010-11-04 |
Abbott Gmbh & Co. Kg. |
Composes de benzenesulfonanilide pour le traitement de troubles repondant a la modulation du recepteur 5-ht6 de la serotonine
|
US8362010B2
(en)
|
2009-04-30 |
2013-01-29 |
Abbott Gmbh & Co. Kg |
Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
|
SG175187A1
(en)
|
2009-04-30 |
2011-11-28 |
Abbott Gmbh & Co Kg |
N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
|
US8343959B2
(en)
|
2009-04-30 |
2013-01-01 |
Abbott Gmbh & Co. Kg |
N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
|
SG181992A1
(en)
|
2010-01-05 |
2012-08-30 |
Suven Life Sciences Ltd |
Sulfone compounds as 5-ht6 receptor ligands
|
CN103221410B
(zh)
|
2010-09-22 |
2017-09-15 |
艾尼纳制药公司 |
Gpr119受体调节剂和对与其相关的障碍的治疗
|
WO2012059432A1
(fr)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
Composés de type n-phényl-(homo)pipérazinyl-benzènesulfonyle ou benzènesulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6
|
WO2012059431A1
(fr)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
Composés de type benzènesulfonyle ou sulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6 de la sérotonine
|
ES2413911B1
(es)
*
|
2011-12-15 |
2014-05-14 |
Universidad De Zaragoza |
Agente inhibidor de la agregación del peptido beta amiloide.
|
EP2828238B1
(fr)
|
2012-03-20 |
2016-05-25 |
Adamed Sp. z o.o. |
Dérivés de sulfonamide de la benzylamine pour le traitement de maladies du système nerveux central (snc)
|
ES2738493T3
(es)
|
2013-03-14 |
2020-01-23 |
Tolero Pharmaceuticals Inc |
Inhibidores de JAK2 y ALK2 y métodos para su uso
|
CN105531272B
(zh)
|
2013-07-25 |
2017-12-22 |
雅盖隆大学 |
作为5‑ht6拮抗剂的吡咯并喹啉衍生物、其制备方法和用途
|
WO2015158313A1
(fr)
|
2014-04-19 |
2015-10-22 |
Sunshine Lake Pharma Co., Ltd. |
Dérivés de sulfonamide et leurs applications pharmaceutiques
|
CN105367472B
(zh)
*
|
2014-08-12 |
2020-04-21 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
CN105367473B
(zh)
*
|
2014-08-12 |
2020-02-11 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
NZ734220A
(en)
|
2015-01-06 |
2022-01-28 |
Arena Pharm Inc |
Methods of treating conditions related to the s1p1 receptor
|
EP4119141A1
(fr)
|
2015-06-12 |
2023-01-18 |
Axovant Sciences GmbH |
Nelotanserin pour la prophylaxie et le traitement d'un trouble du comportement en sommeil paradoxal
|
IL285890B
(en)
|
2015-06-22 |
2022-07-01 |
Arena Pharm Inc |
Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
|
BR112018000728A2
(pt)
|
2015-07-15 |
2018-09-04 |
Axovant Sciences Gmbh |
resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
|
CN108926565A
(zh)
*
|
2017-05-26 |
2018-12-04 |
中国科学院上海生命科学研究院 |
五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
|
WO2019180176A1
(fr)
|
2018-03-21 |
2019-09-26 |
Spherium Biomed, S.L. |
Composition pour le traitement de la schizophrénie et/ou de la psychose
|
CA3103995A1
(fr)
|
2018-07-26 |
2020-01-30 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Procedes de traitement de maladies associees a l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destines a etre utilises dans ceux-ci
|